DNTOX

Dusseldorf, Germany Founded: 2022 • Age: 4 yrs
Chemical testing and development services are provided by DNTOX.
Annual revenue - Latest available
Total funding $1.5M 1 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About DNTOX

DNTOX is a company based in Dusseldorf (Germany) founded in 2022 by Katharina Koch and Kristina Bartmann. DNTOX has raised $1.53 million across 1 funding round from investors including High-Tech Gründerfonds, Bool Capital and AQAL. DNTOX offers products and services including Developmental Neurotoxicity Testing and Adult Neurotoxicity Testing.

  • Headquarter Dusseldorf, Germany
  • Founders Katharina Koch, Kristina Bartmann
  • Sectors
    Chemicals & Materials
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Dntox Gmbh
Operational Areas
Chemicals & Materials → Industrial & Technical Services Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $1.53 M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.53 M (USD), Seed

    Jun 19, 2023

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of DNTOX

DNTOX offers a comprehensive portfolio of products and services, including Developmental Neurotoxicity Testing and Adult Neurotoxicity Testing.

Product name locked
Category locked
Primary

Chemicals are evaluated for potential disturbances in brain development using multicellular and multiplexed human-based 2D/3D in vitro systems.

Product name locked
Category locked
Locked

Compounds are assessed for neurotoxicity effects through 3D hiPSC-derived BrainSpheres on multi-electrode arrays to identify neurotransmitter receptor subtypes.

Funding Insights of DNTOX

DNTOX has successfully raised a total of $1.53M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.53 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in DNTOX

DNTOX has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include High-Tech Gründerfonds, Bool Capital and AQAL.

All
Venture Fund
Investor Description Founded Year Domain Location
Early-stage investments are made in high-tech startups by HTGF.
Locked Locked Locked
-
Locked Locked Locked
AQAL is engaged in integral investing for sustainable prosperity.
Locked Locked Locked
Premium access

Investor details for DNTOX

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by DNTOX

Investments
Premium access

Investment portfolio details for DNTOX

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - DNTOX

Premium access

Detailed financials for DNTOX

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Dntox Comparisons

DNTOX Primary company
Description
Chemical testing and development services are provided by DN...
Location
Dusseldorf, Germany
Founded Year
2022
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for DNTOX

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of DNTOX

Premium access

Detailed competitors of DNTOX

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Dntox

Premium access

Complete news archive for DNTOX

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about DNTOX

DNTOX was founded in 2022 and raised its 1st funding round 1 year after it was founded.

DNTOX is headquartered in Dusseldorf, Germany. It is registered at Dusseldorf, North Rhine-westphalia, Germany.

DNTOX is a funded company, having raised a total of $1.53M across 1 funding round to date.

DNTOX was founded in 2022 in Dusseldorf, Germany, by co-founders Katharina Koch and Kristina Bartmann. Operations focus on the chemical sector, where testing and development services are delivered to clients. The company maintains a presence through its domain dntox.de, supporting activities in chemical analysis and innovation within the European market. Services encompass various testing protocols and developmental processes tailored to industry needs.

DNTOX offers Developmental Neurotoxicity Testing and Adult Neurotoxicity Testing.

DNTOX has 3 investors. Key investors include High-Tech Gründerfonds, Bool Capital, and AQAL.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available